VTVT - vTv Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

44.16M

Cash

12.61M

Avg Qtr Burn

-6.76M

Short % of Float

4.99%

Insider Ownership

64.47%

Institutional Own.

4.45%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TTP399 (GLP-1R agonists) Details Type 1 diabetes, Diabetes	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HPP737 (PDE4 inhibitor) Details Psoriasis, Skin disease/disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP399 (GLP-1R agonists) Details Diabetes, Type 2 diabetes	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.